$0.87
+0.13 (+17.23%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where IVVD is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
7 interventional · 1 expanded access · 2 with posted results
Held by 9 tracked-famous managers (MAVERICK CAPITAL LTD, Point72 Asset Management, L.P., CITADEL ADVISORS LLC, Qube Research & Technologies Ltd, TWO SIGMA INVESTMENTS, LP, +4 more) · FINRA short interest 8.9 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study of VYD2311 for the Prevention of COVID-19NCT07298434RT-PCR-confirmed symptomatic COVID-19 through Day 90Randomized · Quadruple-masked · Prevention | Phase 3 | Active, not recruiting | Drug: VYD2311-SD, VYD2311-MD, Placebo | COVID-19 | 1,770 | Aug 2026 | ≤ 12 d | 2026-06-10 |
| Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 VaccineNCT07655180Assessment of safety based on treatment emergent adverse events, injection site reactions, and hypersensitivity reactions through day 6Randomized · Triple-masked · Prevention | Phase 3 | Recruiting | Drug: COVID-19 mRNA vaccine, VYD2311, Placebo (Normal Saline) | COVID-19 | 210 | Aug 2026 | ≤ 12 d | 2026-06-17 |
| A Study of the Investigational Monoclonal Antibody, VYD2311, in Healthy ParticipantsNCT06523153Incidence of TEAEs (including AEs and SAEs)Randomized · Quadruple-masked · Other | Phase 1 | Active, not recruiting | Biological: VYD2311 · Other: Placebo | COVID-19 | 40 | May 2025 | — | 2024-11-19 |
| A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2NCT06039449Cohort A - Incidence of treatment emergent adverse eventsRandomized · Quadruple-masked · Prevention | Phase 3 | Completed | Drug: VYD222 (pemivibart), Normal saline | COVID-19, SARS-CoV-2 | 790 | 2024-11-19actual | — | 2024-12-09 |
| A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of the Monoclonal Antibody VYD222 in Healthy Adult ParticipantsNCT05791318Incidence of TEAEs (including AEs and SAEs)Randomized · Quadruple-masked · Other | Phase 1 | Completed | Drug: VYD222 · Other: Placebo | COVID-19 | 30 | 2024-05-08actual | — | 2024-05-31 |
| Evaluation of ADG20 for the Prevention of COVID-19NCT04859517results2024-08-20Percentage of Participants With RT-PCR Confirmed Symptomatic COVID-19 (PEP)Randomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Terminatedsponsor's stated reason: All primary efficacy data has been collected and analyzed. Based on the safety data gathered to date, it has been determined that continued participation by study subjects would not yield any additional beneficial safety information. | Drug: ADG20, Placebo | COVID-19 | 2,582 | 2022-11-04actual | — | 2024-08-20 |
| Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19NCT04805671results2024-02-06Incidence of COVID-19 Related Hospitalizations or All-cause DeathRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Terminatedsponsor's stated reason: All primary efficacy data has been collected and analyzed. Based on the safety data gathered to date, it has been determined that continued participation by study subjects would not yield any additional beneficial safety information. | Drug: ADG20, Normal saline | COVID-19 | 399 | 2022-02-10actual | — | 2024-02-06 |
| Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other TreatmentsNCT06004128expanded access | — | No longer available | Drug: VYD222 | COVID-19 | — | — | — | 2024-06-03 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19